help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2007-1253
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
92/12/4865    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thouënnon, E.
Right arrow Articles by Anouar, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thouënnon, E.
Right arrow Articles by Anouar, Y.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Pheochromocytoma
Related Collections
Right arrow Adrenal and Hypertension
Right arrow Cardiovascular Endocrinology
Right arrow Endocrine Oncology
The Journal of Clinical Endocrinology & Metabolism Vol. 92, No. 12 4865-4872
Copyright © 2007 by The Endocrine Society


BRIEF REPORT

Identification of Potential Gene Markers and Insights into the Pathophysiology of Pheochromocytoma Malignancy

Erwan Thouënnon, Abdel G. Elkahloun, Johann Guillemot, Anne-Paule Gimenez-Roqueplo, Jérôme Bertherat, Alice Pierre, Hafida Ghzili, Luca Grumolato, Mihaela Muresan, Marc Klein, Hervé Lefebvre, L’Houcine Ouafik, Hubert Vaudry, Pierre-François Plouin, Laurent Yon and Youssef Anouar

Institut National de la Santé et de la Recherche Médicale U413 (E.T., J.G., A.P., H.G., L.G., H.L., H.V., L.Y., Y.A.), Laboratory of Cellular and Molecular Neuroendocrinology, European Institute for Peptide Research (Institut Fédératif de Recherche Multidisciplinaires sur les Peptides 23), University of Rouen, 76821 Mont-Saint-Aignan, France; Genome Technology Branch (A.G.E.), National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892; Department of Genetics (A.-P.G.-R.), Hôpital Européen Georges Pompidou, 75015 Paris, France; Department of Endocrinology (J.B.), Institut National de la Santé et de la Recherche Médicale U567, Institut Cochin, 75014 Paris, France; Department of Endocrinology (M.M., M.K.), Hôpital de Brabois, 54511 Nancy, France; Equipe Mixte Institut National de la Santé et de la Recherche Médicale EMI 0359 (L.O.), Laboratory of Experimental Cancerology, Université de la Mediterranée, Aix-Marseille II, 13015 Marseille, France; and Hypertension Unit (P.-F.P.), Hôpital Européen Georges Pompidou, AP-HP, University of Paris-5, 75015 Paris, France

Address all correspondence and requests for reprints to: Dr. Y. Anouar, Institut National de la Santé et de la Recherche Médicale U413, Laboratory of Cellular and Molecular Neuroendocrinology, Institut Fédératif de Recherche Multidisciplinaires sur les Peptides 23, University of Rouen, 76821 Mont-Saint-Aignan, France. E-mail: youssef.anouar{at}univ-rouen.fr.

Context: Pheochromocytomas are catecholamine-producing tumors that are generally benign but that can also present as or develop into malignancy. Occurrence of malignant pheochromocytomas can only be asserted by imaging of metastatic lesions.

Objectives: We conducted a gene expression profiling of benign and malignant tumors to identify a gene signature that would allow us to discriminate benign from malignant pheochromocytomas and to gain a better understanding of tumorigenic pathways associated with malignancy.

Design: A total of 36 patients with pheochromocytoma was studied retrospectively. There were 18 (nine benign and nine malignant) tumors used for gene expression profiling on pangenomic oligonucleotide microarrays.

Results: We identified and validated a set of predictor genes that could accurately distinguish the two tumor subtypes through unsupervised clustering. Most of the differentially expressed genes were down-regulated in malignant tumors, and several of these genes encoded neuroendocrine factors involved in prominent characteristics of chromaffin cell biology. In particular, the expression of two key processing enzymes of trophic peptides, peptidylglycine {alpha}-amidating monooxygenase and glutaminyl-peptide cyclotransferase, was reduced in malignant pheochromocytomas.

Conclusion: The gene expression profiling of benign and malignant pheochromocytomas clearly identified a set of genes that could be used as a prognostic multi-marker and revealed that the expression of several genes encoding neuroendocrine proteins was reduced in malignant compared with benign tumors.




This article has been cited by other articles:


Home page
The OncologistHome page
J. T. Adler, G. Y. Meyer-Rochow, H. Chen, D. E. Benn, B. G. Robinson, R. S. Sippel, and S. B. Sidhu
Pheochromocytoma: Current Approaches and Future Directions
Oncologist, July 1, 2008; 13(7): 779 - 793.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society